| [1] | Mueller, S., de Andrade Krätzig, N., Tschurtschenthaler, M., et al. (2026). A disease model resource reveals core principles of tissue-specific cancer evolution. Nature. DOI: 10.1038/s41586-026-10187-2. |
| [2] | Juul, N.H., Yoon, J.K., Martinez, M.C., et al. (2023). KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming. Nature 619(7971):860−867. DOI:10.1038/s41586-023-06324-w |
| [3] | Costa, B., Fletcher, M.N.C., Boskovic, P., et al. (2021). A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors. Cancers (Basel) 13(2). DOI: 10.3390/cancers13020230. |
| Chen Y. and Yang C. (2026). Tissue-specific cancer evolution: Deciphering deterministic rules to shape precision medicine. The Innovation Drug Discovery 1:100014. https://doi.org/10.59717/j.xinn-drugdisc.2026.100014 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
A framework for tissue-specific cancer evolution and drug development based on the MCCA